An observational study in Acute Myeloid Leukemia, sponsored by University Hospital, Toulouse. Active, not recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-30.
Sponsored by University Hospital, Toulouse · Observational
The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.
Diagnosis of acute myeloid leukemia between 2000 and 2014 in 2 hospitals in South of France
Inclusion Criteria:
patients treated with intensive chemotherapy
Drug: intensive chemotherapy
patients treated with azacitidine
Drug: Azacitidine
Survival
Survival times
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse